XML 62 R13.htm IDEA: XBRL DOCUMENT v3.2.0.727
Marketable Securities
6 Months Ended
Jun. 30, 2015
Available-for-sale Securities [Abstract]  
Marketable Securities
Marketable Securities
Rambus invests its excess cash and cash equivalents primarily in U.S. government sponsored obligations, commercial paper, corporate notes and bonds, money market funds and municipal notes and bonds that mature within three years.  As of June 30, 2015 and December 31, 2014, all of the Company’s cash equivalents and marketable securities had a remaining maturity of less than one year.
All cash equivalents and marketable securities are classified as available-for-sale. Total cash, cash equivalents and marketable securities are summarized as follows:
 
 
As of June 30, 2015
(In thousands)
 
Fair Value
 
Amortized
 Cost
 
Gross
 Unrealized
 Gains
 
Gross
 Unrealized
 Losses
 
Weighted
 Rate of
 Return
Money market funds
 
$
175,972

 
$
175,972

 
$

 
$

 
0.01
%
Corporate notes, bonds and commercial paper
 
146,649

 
146,735

 
2

 
(88
)
 
0.40
%
Total cash equivalents and marketable securities
 
322,621

 
322,707

 
2

 
(88
)
 
 

Cash
 
25,505

 
25,505

 

 

 
 

Total cash, cash equivalents and marketable securities
 
$
348,126

 
$
348,212

 
$
2

 
$
(88
)
 
 

 
 
As of December 31, 2014
(In thousands)
 
Fair Value
 
Amortized
 Cost
 
Gross
 Unrealized
 Gains
 
Gross
 Unrealized
 Losses
 
Weighted
 Rate of
 Return
Money market funds
 
$
124,938

 
$
124,938

 
$

 
$

 
0.01
%
Corporate notes, bonds and commercial paper
 
145,983

 
146,096

 
1

 
(114
)
 
0.25
%
Total cash equivalents and marketable securities
 
270,921

 
271,034

 
1

 
(114
)
 
 

Cash
 
29,188

 
29,188

 

 

 
 

Total cash, cash equivalents and marketable securities
 
$
300,109

 
$
300,222

 
$
1

 
$
(114
)
 
 



Available-for-sale securities are reported at fair value on the balance sheets and classified as follows:
 
As of
 
June 30,
2015
 
December 31,
2014
 
(In thousands)
Cash equivalents
$
175,972

 
$
124,938

Short term marketable securities
146,649

 
145,983

Total cash equivalents and marketable securities
322,621

 
270,921

Cash
25,505

 
29,188

Total cash, cash equivalents and marketable securities
$
348,126

 
$
300,109



The Company continues to invest in highly rated quality, highly liquid debt securities. As of June 30, 2015, these securities have a remaining maturity of less than one year. The Company holds all of its marketable securities as available-for-sale, marks them to market, and regularly reviews its portfolio to ensure adherence to its investment policy and to monitor individual investments for risk analysis, proper valuation, and unrealized losses that may be other than temporary.

The estimated fair value of cash equivalents and marketable securities classified by the length of time that the securities have been in a continuous unrealized loss position at June 30, 2015 and December 31, 2014 are as follows:
 
Fair Value
 
Gross Unrealized Loss
 
June 30,
2015
 
December 31,
2014
 
June 30,
2015
 
December 31,
2014
 
(In thousands)
Less than one year
 

 
 

 
 

 
 

Corporate notes, bonds and commercial paper
$
126,434

 
$
139,989

 
$
(88
)
 
$
(114
)


The gross unrealized loss at June 30, 2015 and December 31, 2014 was not material in relation to the Company’s total available-for-sale portfolio. The gross unrealized loss can be primarily attributed to a combination of market conditions as well as the demand for and duration of the corporate notes and bonds. There is no requirement to sell and the Company believes that it can recover the amortized cost of these investments. The Company has found no evidence of impairment due to credit losses in its portfolio. Therefore, these unrealized losses were recorded in other comprehensive income (loss). However, the Company cannot provide any assurance that its portfolio of cash, cash equivalents and marketable securities will not be impacted by adverse conditions in the financial markets, which may require the Company in the future to record an impairment charge for credit losses which could adversely impact its financial results.
See Note 7, “Fair Value of Financial Instruments,” for discussion regarding the fair value of the Company’s cash equivalents and marketable securities.